70.53% of the stock is owned by institutional investors and hedge funds. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) traded down 1.94% during trading on Wednesday, reaching $4.55. The company’s stock had …
Spectrum Pharmaceuticals
It was a rough third quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 7% during the quarter. The Russell 2000, composed of smaller …
Science and Public Policy Institute
This is a proprietary realized volatility rating created by Capital Market Laboratories (CMLviz) based on a large number of data interactions for Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) . We examine the little …
A sizeable “surprise factor” can lead to a large change in the stock’s price during the time immediately …
The stock of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) hit a new 52-week low and has $3.47 target or 14.00% below today’s $4.03 share price. The 9 months bearish chart indicates high risk for the $301.16 million …
While the FDA can still vote to approve the drug in its final ruling in mid-December, SPPI stock is down 5.3% this afternoon at $5.20, after earlier being halted for volatility. This negative price action is nothing new for SPPI, …
Luna Emery is a financial writer. She graduated with a degree in Economics. She has contributed to major financial websites and print publications for over 8 years. She handles much of this site's news coverage for …
ETFs by nature are passive index-followers, so as long as the stock remains in the index, it doesn't much matter whether analysts find the stock overvalued or undervalued. Below are some of the ETFs that hold SPPI at last …
Spectrum Pharmaceutical's (NASDAQGS: SPPI) has seen sales for FUSILEV grow dramatically in the last year and these sales have been, and continue to be, the primary driver of the stock. Prior to the survey of …
Sales
The FDA told Spectrum not to seek approval for its bladder cancer drug. Spectrum filed anyway but never told investors about the FDA warning. An FDA committee said on Wednesday that Spectrum Pharmaceuticals' …